BioCentury | Nov 7, 2020
Emerging Company Profile

Vaxxinity: supplanting mAbs with vaccines for chronic disease

...2020 by Mei Mei Hu, Lou ReeseUniversity collaborators: University of Nebraska Medical Center...
BioCentury | Feb 26, 2020
Product Development

U.S. testing of coronavirus vaccine, therapeutic begin

...of remdesivir from Gilead Sciences Inc. (NASDAQ:GILD). The study, which is being conducted at the University of Nebraska Medical Center...
...last week. Of the 13 people repatriated and transported to the National Quarantine Unit at UNMC...
BioCentury | Jul 18, 2019
Translation in Brief

What Excision needs to demonstrate before bringing CRISPR-HIV therapy to clinic

...CRISPR-mediated off-target effects in the mice. Elizabeth S. Eaton, Staff Writer Excision BioTherapeutics Inc. National Institutes of Health Temple University University of Nebraska Medical Center HIV/AIDS CRISPR HIV Tony...
BioCentury | Jul 18, 2019
Distillery Therapeutics

CRISPR plus antiretroviral therapy could remove HIV virus from cells

...Kamel Khalili, Temple University, Philadelphia, Pa. e-mail: kamel.khalili@temple.edu CONTACT: Howard Gendelman, University of Nebraska Medical Center, Omaha, Neb. e-mail: hegendel@unmc.edu Elizabeth...
BioCentury | Oct 3, 2018
Distillery Therapeutics

Neurology

...published online Sept. 24, 2018 doi:10.1021/acs.jmedchem.8b00994 CONTACT: Corey R. Hopkins, Vanderbilt University, Nashville, Tenn. email: corey.hopkins@unmc.edu Claire...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Hello RNA

...Breast cancer Cell-based; mouse; patient sample Inhibiting EHD2 could help treat triple-negative breast cancer (TNBC). University of Nebraska Medical Center...
...PAF1) Prostate cancer Cell-based Inhibiting PAF1 could restore sensitivity to docetaxel in resistant prostate cancers. University of Nebraska Medical Center...
BioCentury | Feb 14, 2018
Distillery Therapeutics

Infectious disease

...published online Feb. 6, 2018 doi:10.1038/s41467-018-02885-x CONTACT: Howard Gendelman, University of Nebraska Medical Center, Omaha, Neb. email: hegendel@unmc.edu Hongjiang Li Tivicay University of Nebraska Medical Center HIV...
BioCentury | Jan 12, 2017
Clinical News

TGR-1202: Ph IIa started

...TG Therapeutics said the University of Nebraska Medical Center began an open-label, U.S. Phase IIa trial to evaluate once-daily oral...
BioCentury | Sep 29, 2016
Distillery Therapeutics

Therapeutics: NADPH oxidase 2 (NOX2)

...Med.; published online Aug. 15, 2016 doi:10.1084/jem.20150514 CONTACT: Keer Sun, University of Nebraska Medical Center , Omaha, Neb. email: Keer.sun@unmc.edu BC...
BioCentury | Apr 14, 2016
Product R&D

AACR by the numbers

...in human colon cancer cell lines suggest inhibiting TIMELESS could help treat Ras-driven colon cancers. University of Nebraska Medical Center...
Items per page:
1 - 10 of 43
BioCentury | Nov 7, 2020
Emerging Company Profile

Vaxxinity: supplanting mAbs with vaccines for chronic disease

...2020 by Mei Mei Hu, Lou ReeseUniversity collaborators: University of Nebraska Medical Center...
BioCentury | Feb 26, 2020
Product Development

U.S. testing of coronavirus vaccine, therapeutic begin

...of remdesivir from Gilead Sciences Inc. (NASDAQ:GILD). The study, which is being conducted at the University of Nebraska Medical Center...
...last week. Of the 13 people repatriated and transported to the National Quarantine Unit at UNMC...
BioCentury | Jul 18, 2019
Translation in Brief

What Excision needs to demonstrate before bringing CRISPR-HIV therapy to clinic

...CRISPR-mediated off-target effects in the mice. Elizabeth S. Eaton, Staff Writer Excision BioTherapeutics Inc. National Institutes of Health Temple University University of Nebraska Medical Center HIV/AIDS CRISPR HIV Tony...
BioCentury | Jul 18, 2019
Distillery Therapeutics

CRISPR plus antiretroviral therapy could remove HIV virus from cells

...Kamel Khalili, Temple University, Philadelphia, Pa. e-mail: kamel.khalili@temple.edu CONTACT: Howard Gendelman, University of Nebraska Medical Center, Omaha, Neb. e-mail: hegendel@unmc.edu Elizabeth...
BioCentury | Oct 3, 2018
Distillery Therapeutics

Neurology

...published online Sept. 24, 2018 doi:10.1021/acs.jmedchem.8b00994 CONTACT: Corey R. Hopkins, Vanderbilt University, Nashville, Tenn. email: corey.hopkins@unmc.edu Claire...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Hello RNA

...Breast cancer Cell-based; mouse; patient sample Inhibiting EHD2 could help treat triple-negative breast cancer (TNBC). University of Nebraska Medical Center...
...PAF1) Prostate cancer Cell-based Inhibiting PAF1 could restore sensitivity to docetaxel in resistant prostate cancers. University of Nebraska Medical Center...
BioCentury | Feb 14, 2018
Distillery Therapeutics

Infectious disease

...published online Feb. 6, 2018 doi:10.1038/s41467-018-02885-x CONTACT: Howard Gendelman, University of Nebraska Medical Center, Omaha, Neb. email: hegendel@unmc.edu Hongjiang Li Tivicay University of Nebraska Medical Center HIV...
BioCentury | Jan 12, 2017
Clinical News

TGR-1202: Ph IIa started

...TG Therapeutics said the University of Nebraska Medical Center began an open-label, U.S. Phase IIa trial to evaluate once-daily oral...
BioCentury | Sep 29, 2016
Distillery Therapeutics

Therapeutics: NADPH oxidase 2 (NOX2)

...Med.; published online Aug. 15, 2016 doi:10.1084/jem.20150514 CONTACT: Keer Sun, University of Nebraska Medical Center , Omaha, Neb. email: Keer.sun@unmc.edu BC...
BioCentury | Apr 14, 2016
Product R&D

AACR by the numbers

...in human colon cancer cell lines suggest inhibiting TIMELESS could help treat Ras-driven colon cancers. University of Nebraska Medical Center...
Items per page:
1 - 10 of 43